目的 探讨肺癌中表皮生长因子受体(epidermal growth factor receptor,EGFR)突变状态与甲状腺转录因子-1(thyroid transcription factor-1,TTF-1)表达,以及与临床病理特征之间的关系。方法 收集40例手术切除肺癌标本,采用扩增阻滞预编系统(ARMS)法和PCR技术检测肺癌组织中EGFR基因的突变情况。分析肺癌的临床病理特征、肿瘤组织学类型与EGFR突变的关系。结果 40例中,EGFR基因突变概率为57.5%(23/40),且突变率因性别、吸烟史、肿瘤组织学类型及TTF-1表达的不同而具有统计学差异(P<0.05)。结论 肺癌中EGFR基因的突变状态与TTF-1表达、组织学类型、患者性别、吸烟史有关。TTF-1强表达的女性、不吸烟的腺癌患者中EGFR具有更高的突变率。
Abstract
Objective To investigate the relationship epidermal growth factor receptor (epidermal growth factor receptor, EGFR) mutation status and thyroid transcription factor-1 (thyroid transcription factor-1, TTF-1) between the expression and clinical pathological characteristics in the lung cancer. Methods From 40 patients of operatively resected lung cancer specimens were collected.Using amplification refractory pre system (ARMS) and polymerase chain reaction (PCR), mutation of EGFR gene in lung cancer tissue was detected. Histological typingwas according to the 2011 WHO classification operation specimens. The analysis of relationship between EGFR mutation and TTF-1 expression and clinical pathological characteristics in the lung cancers was analyzed using the statistical software of SPSS17.0. Results In 40 patients with lung cancer, EGFR gene mutation probability was 57.5% (23/40). EGFR gene mutation related to lung cancer patient’s sex, smoking history, lung cancer’s subtype and TTF-1 expression (P<0.05). Conclusions In lung cancer, EGFR gene mutation status is related to TTF-1 expression and histological type, gender, history of smoking. Thewomenwith strong expression of TTF-1,without smoking history and adeno-carcinoma patients have the higher EGFR mutation rate.
关键词
肺癌 /
表皮生长因子受体 /
甲状腺转录因子 /
病理学特征
Key words
lung cancer /
epidermal growth factor receptor /
thyroid transcription factor-1 /
clinical characteristics
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Herbst R S,Heymach J V,Lippman S M. Lung cancer[J].N Engl J Med, 2008,359:1367-1380.
[2] Jemal A,Bray F,Center M. Global cancer statistics,2011[J].CA Cancer J Clin,2011,61:69-90.
[3] Sequist L V, Lynch T J. EGFR tyrosine kinase inhibitors in lung cancer: an evolving story[J].Annu Rev Med,2008,59:429-442.
[4] Burgess D J.Cancer genetics: initially complex, always heterogeneous[J].Nat Rev Cancer,2011,11:153.
[5] Bunnell C A, Shulman L N. Will we be able to care for cancer patients in the future?[J].Oncology (Williston Park),2010,14:1343-1348.
[6] Sharma S V, Bell D W, Settleman J,et al. Epidermal growth factor receptor mutations in lung cancer[J].Nat Rev Cancer,2007,7:169-181.
[7] Lynch T J,Bell D W,Sordella R,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib[J].N Engl J Med,2004,350:2129-2139.
[8] Paez J G. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy[J].Science,2004,304:1497-1500.
[9] Pao W,Miller V. EGFR receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib[J].Proc Natl Acad Sci USA,2004,101:13306-13311.
[10] Yoshida T, Ishii G, Goto K, et al. Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma[J].J Cancer Res Clin Oncol,2013,139(10):1691-1700.
[11] Fukuoka M,Thongprasert S. Biomarker analyses and final overall survival results from a phase ⅡI, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS)[J]. J Clin Oncol,2011,29:2866-2874.
[12] Mok T S,WU Y L, Thongprasert S,et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J].N Engl J Med,2009,361:947-957.
[13] KIM Y H,ISHⅡ G,GOTO K, et al. Dominant papillary subtype is a significant predictor of the response to gefitinib in adenocarcinoma of the lung[J].Clin Cancer Res,2004,10:7311-7317.
[14] 李艳秋,刘 杰,刘瑞青,等.肺腺癌组织学亚型与EGFR突变及临床特征的关系[J].西安交通大学学报(医学版),2014,35(1):94-98.
[15] 刘瑞青,申淑景.肺腺癌组织中TTF-1和SPA的表达对EGFR突变的临床预测价值[J].第三军医大学学报,2012,34(22):78-81.
[16] Eberhard D A, Johnson B E, Amler L C. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib[J].J Clin Oncol,2005,25:5900-5909.
PDF(500 KB)
